SAGE Therapeutics (SAGE) Announced FDA Fast Track Designation for SAGE-547
Tweet Send to a Friend
SAGE Therapeutics (NASDAQ: SAGE) announced today that the FDA has granted fast track designation to the SAGE-547 development program. SAGE-547 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
